RE:#'s outSweet, but not unreasonable - 10% discount on a low share price plus a 3-year warrant at a 25% premium, (I would have subscribed.) Small raise, little dilution, but it will only fund about Q1 2018, so there will be a financing overhang. Hopefully there will good news during that quarter e.g. positive FDA application progress.